Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b/3 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study To Investigate The Efficacy And Safety Of Pf-06651600 In Adult And Adolescent Alopecia Areata (aa) Subjects With 50% Or Greater Scalp Hair Loss

Next Previous
Trial Profile

A Phase 2b/3 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study To Investigate The Efficacy And Safety Of Pf-06651600 In Adult And Adolescent Alopecia Areata (aa) Subjects With 50% Or Greater Scalp Hair Loss

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 24 Jan 2019

At a glance

  • Drugs PF 6651600 (Primary)
  • Indications Alopecia areata
  • Focus Registrational; Therapeutic Use
  • Acronyms ALLEGRO-2b/3
  • Sponsors Pfizer

    • Most Recent Events

    • 08 Jan 2019 Planned End Date changed from 15 Jun 2021 to 28 Mar 2021.
    • 08 Jan 2019 Planned primary completion date changed from 15 Jun 2021 to 28 Mar 2021.
    • 03 Jan 2019 According to a Pfizer media release, the company has initiated this study
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top